Compare Amylx Pharmaceuticals Inc (AMLX) vs Intuitive Surgical, Inc. (ISRG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Intuitive Surgical, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while Intuitive Surgical, Inc. trades at $408.5 (market cap $144.07B). The key difference: Intuitive Surgical, Inc. is far larger — about 72.8× Amylx Pharmaceuticals Inc's market cap, and Amylx Pharmaceuticals Inc is trading nearer its 52-week high, Intuitive Surgical, Inc. nearer its low. Which is the better fit depends on your goals.
| AMLX | ISRG | |
|---|---|---|
Market Cap | $1.98B | $144.07B |
Sector | Health | Health |
52-Week High | $18.70 | $592.85 |
52-Week Low | $7.64 | $397.68 |
Enterprise Value | $1.70B | $139.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
Intuitive Surgical (ISRG) trades at $406.78, down 1.16% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings of $2.50 EPS, beating estimates, with revenue reaching $10.06 billion in 2025 and net income margin at 28.15%. Analyst consensus is bullish with a $556.10 price target, though valuation ratios like P/E of 49.43 remain elevated. Recent news highlights Q2 2026 earnings anticipation on July 16 and ongoing adoption of da Vinci 5 systems.
Outlook is positive due to consistent earnings beats and robust revenue growth, but risks include high valuation sensitivity and competitive pressures. The stock offers long-term growth potential in robotic surgery, yet investors should monitor margin trends and quarterly results for sustained momentum amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Intuitive Surgical, Inc.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →
